Skip to main content
. 2019 Apr 29;18:1534735419846377. doi: 10.1177/1534735419846377

Figure 6.

Figure 6.

Quxie capsule (QX) had an anticancer effect in human colorectal cancer HCT116 cells. (A) Flow cytometry showed apoptotic cells in QX- or vehicle control-treated HCT116 cells with Annexin V-FITC/PI double staining. The lower right quadrant showed annexin-positive cells (early apoptosis), and the upper right quadrant shows cells positive for both annexin and PI (late apoptosis). aP < .01 for QX-treated compared with vehicle-treated HCT116 cells. bP < .01 for QX (0.6 mg/ml)-treated compared with QX (0.3 mg/mL)-treated HCT116 cells. (B) Foxo1 protein expression in QX-treated HCT116 cells. *P < .05 versus vehicle control. (C) Foxo1 protein expression in FOXO1 siRNA-silenced HCT116 cells. (D) Cell viability in QX-treated Foxo1 siRNA and control siRNA-transfected HCT116 cells. aP < .05 for QX-treated control siRNA-transfected cells compared with vehicle-treated controls. bP < .05 for QX-treated FOXO1 siRNA transfected cells compared with QX-treated control siRNA-transfected cells. Data are presented as mean ± SD.